Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...

Led by Guido Marcucci, M.D., City of Hope professor and chair, Department of Hematologic Malignancies Translational Science, director, Gehr Family Center for Leukemia Research, and chief, Division of ...

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Please provide your email address to receive an email when new articles are posted on . Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.